Welcome
Support Centre
21 March 2013 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
A trial comparing conventional fractionation with 'CHART' in the treatment of head and neck cancer
ISRCTN ISRCTN68133429
DOI 10.1186/ISRCTN68133429
ClinicalTrials.gov identifier
EudraCT number
Public title A trial comparing conventional fractionation with 'CHART' in the treatment of head and neck cancer
Scientific title
Acronym N/A
Serial number at source CH02
Study hypothesis To compare the effectiveness of radical fractionated radiotherapy given daily over 6 weeks with CHART over 12 days, with respect to local tumour control, survival and morbidity
Lay summary Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Cancer
Participants - inclusion criteria 1. Histologically proven squamous cell carcinoma of all grades at one of the following sites: Nasal sinuses, Nasopharynx, Oral cavity, Oropharynx, Hypopharynx, Carcinoma of the larynx
2. A radical course of external beam radiotherapy is the appropriate sole treatment
Participants - exclusion criteria There should be no evidence of distant metastases beyond the regional nodes in the neck
Anticipated start date 01/01/1990
Anticipated end date 01/03/1995
Status of trial Completed
Patient information material
Target number of participants 500
Interventions Conventional radiotherapy arm - 2 Gy, once daily five days a week over six weeks (large volume - 44 Gy in 22 fractions followed by small volume - 16 Gy in eight fractions)

CHART arm - 1.5 Gy, three time daily over 12 treatment days (large volume - 37.5 Gy in 25 fractions followed by small volume - 16.5 Gy in 11 fractions)
Primary outcome measure(s) 1. Local tumour control
2. Survival
3. Morbidity
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Medical Research Council (MRC) (UK)
Trial website
Publications
Contact name Dr  James  Lyddiard
  Address MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Email
Sponsor Medical Research Council (MRC) (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 28/02/2001
Last edited 05/11/2012
Date ISRCTN assigned 28/02/2001
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2013 ISRCTN unless otherwise stated.